Liranaftate (trade name Zefnart) is a topical antifungal drug.[1] It is used as a 2% cream used to treat tinea pedis (athlete's foot), tinea corporis (ringworm), and tinea cruris (jock itch).[2] It was approved for use in Japan in August 2000.[3][4]

Liranaftate
Clinical data
Trade namesZefnart
Other namesM-732; piritetrate
Routes of
administration
Topical
ATC code
Legal status
Legal status
  • JP: Rx-only
Identifiers
  • O-(5,6,7,8-Tetrahydronaphthalen-2-yl) N-(6-methoxypyridin-2-yl)-N-methylcarbamothioate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H20N2O2S
Molar mass328.43 g·mol−1

Liranaftate works by inhibiting the fungal enzyme squalene epoxidase that is necessary for the fungus to synthesize sterols which are essential for cell membrane integrity.[5]

References

edit
  1. ^ Koga H, Nanjoh Y, Makimura K, Tsuboi R (2009). "In vitro antifungal activities of luliconazole, a new topical imidazole". Medical Mycology. 47 (6): 640–7. doi:10.1080/13693780802541518. PMID 19115136.
  2. ^ "Torii Pharmaceutical to Launch Antifungal Agent for External Use, "ZEFNART SOLUTION 2%", in Japan" (Press release). Torii Pharmaceutical Co. Retrieved June 27, 2021.
  3. ^ "Liranaftate". ncats.io. Retrieved June 27, 2021.
  4. ^ "Liranaftate". Adis Insight. Retrieved June 27, 2021.
  5. ^ CID 3936 from PubChem